Astellas Pharma Inc: Ovarian Neoplasms trials
The registry lists 13 Ovarian Neoplasms studies with Astellas Pharma Inc as lead sponsor. 0 are open to participants now and 1 have results posted.
Phase 1 12Phase 2 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression ParticipantsTerminatedNCT04939701Phase 1/2Results posted
- XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.Active, not recruitingNCT06792435Phase 1/2
- A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid TumorsWithdrawnNCT06681870Phase 1
- A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid TumorsCompletedNCT03565445Phase 1
- Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)CompletedNCT02054351Phase 1
- A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian CancerTerminatedNCT01016054Phase 1
- A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)CompletedNCT00889382Phase 1/2
- A Phase 1 Study of the Safety and Pharmacokinetics of AGS-8M4 in Subjects With Advanced Ovarian CancerCompletedNCT00816764Phase 1
- Phase I Study of OSI-930 and Erlotinib in Cancer TumorsCompletedNCT00603356Phase 1
- Study of Intermittent OSI-906 DosingCompletedNCT00514306Phase 1
- Study of Continuous OSI-906 DosingCompletedNCT00514007Phase 1
- Phase 1 Study of OSI-930 in Cancer PatientsCompletedNCT00513851Phase 1
- Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian CancerCompletedNCT00046800Phase 2